EC
TCRR

EcoR1 Capital’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

EcoR1 Capital’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-239,500
Closed -$3.42M – 63
2019
Q4 		$3.42M Buy
+239,500
New +$3.7M 0.31% 40
2019
Q3 		– Sell
-16,114
Closed -$231K – 48
2019
Q2 		$231K Buy
+16,114
New +$257K 0.02% 39

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital's TCRR Position: Q1 2020 in Review

EcoR1 Capital sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q1 2020, closing a stake of 239,500 shares — an estimated $3.42M sold.

EcoR1 Capital first reported a position in TCRR in Q2 2019 and held it in 2 quarters. The position peaked at $3.42M in Q4 2019. 50 funds tracked by Wall St. Rank hold TCRR as of Q1 2020.

  • EcoR1 Capital reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • EcoR1 Capital sold 239,500 TCR2 Therapeutics Inc. Common Stock shares in Q1 2020, an estimated $3.42M.
  • EcoR1 Capital first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2019 and held it in 2 quarters.
  • EcoR1 Capital's TCR2 Therapeutics Inc. Common Stock position peaked at $3.42M in Q4 2019.
  • 50 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q1 2020.

Based on EcoR1 Capital's 13F filing for Q1 2020, filed 15 May 2020.